Supernus Pharmaceuticals (SUPN)
(Delayed Data from NSDQ)
$28.96 USD
-1.04 (-3.47%)
Updated May 10, 2024 03:59 PM ET
After-Market: $28.95 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum C VGM
Price, Consensus and EPS Surprise
SUPN 28.96 -1.04(-3.47%)
Will SUPN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for SUPN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SUPN
Compared to Estimates, Supernus (SUPN) Q1 Earnings: A Look at Key Metrics
Ahead of Supernus (SUPN) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
SUPN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say
Supernus Pharmaceuticals (SUPN) Lags Q4 Earnings Estimates
Ahead of Supernus (SUPN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Other News for SUPN
Supernus Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Strategic Shifts and Pipeline ...
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
Piper Sandler Remains a Buy on Supernus Pharmaceuticals (SUPN)
Supernus Pharmaceuticals Inc (SUPN) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
Supernus Announces First Quarter 2024 Financial Results